All In Biotech

Free tool

FAERS Monitor: Akten

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022221 or its brand name (Akten, Lidocaine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

89

Serious

69

78% of reports

Hospitalization

39

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective14
  • local anaesthetic systemic toxicity8
  • off label use8
  • vision blurred8
  • visual acuity reduced8
  • overdose7
  • hypertension6
  • product use in unapproved indication6
  • eye pain5
  • visual impairment5
  • vitreous floaters5
  • cystoid macular oedema4
  • fatigue4
  • generalised tonic-clonic seizure4
  • hypotension4

Reports by year received

View as table
YearReports
20122
20134
20148
20151
20165
20181
20193
20202
20217
20224
202344
20243
20251
20264

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,070 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
local anaesthetic systemic toxicitySignal81795.5924.512,516
cystoid macular oedemaSignal4502.8192.71,530
vitreous floatersSignal5120.351.3478
generalised tonic-clonic seizureSignal457.121.9168
visual acuity reducedSignal856.929.4386
eye painSignal520.98.976
vision blurredSignal813.87.183
visual impairmentSignal59.54.130
overdoseSignal77.73.835
hypertensionSignal66.73.124
product use in unapproved indicationSignal65.72.619
hypotensionSignal44.71.88
drug ineffectiveSignal142.51.612
off label useSignal82.21.14
fatigue41.20.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.